Atul Malhotra, Josef Bednarik, Sujatro Chakladar, Julia P Dunn, Terri Weaver, Ron Grunstein, Ingo Fietze, Susan Redline, Ali Azarbarzin, Scott A Sands, Richard J Schwab, Mathijs C Bunck
BACKGROUND: Weight reduction is a standard recommendation for obstructive sleep apnea (OSA) treatment in people with obesity or overweight; however, weight loss can be challenging to achieve and maintain without bariatric surgery. Currently, no approved anti-obesity medication has demonstrated effectiveness in OSA management. This study is evaluating the efficacy and safety of tirzepatide for treatment of moderate to severe OSA in people with obesity. METHODS: SURMOUNT-OSA, a randomized, placebo -controlled, 52-week phase 3 trial, is investigating the efficacy and safety of tirzepatide for treatment of moderate to severe OSA (apnea hypopnea- index ≥15 events/h) in participants with obesity (body mass index ≥30 kg/m2 ) and an established OSA diagnosis...
March 26, 2024: Contemporary Clinical Trials